Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib

Journal of Ophthalmic Inflammation and Infection

Volumn 5, Issue 1, 2015, Pages

  Draganova, Dafina ^a   Kerger, Joseph ^b   Caspers, Laure ^a   Willermain, François ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Chorio retinal folds; Dabrafenib; Serous retinal detachment; Trametinib; Uveitis

Indexed keywords

CORTICOSTEROID; DABRAFENIB; FIBRIN; MITOGEN ACTIVATED PROTEIN KINASE; TRAMETINIB;

ADULT; ANTERIOR EYE CHAMBER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; CORTICOSTEROID THERAPY; CUTANEOUS MELANOMA; DISEASE SEVERITY; DRUG WITHDRAWAL; EYE EXAMINATION; FEMALE; HUMAN; METASTATIC MELANOMA; MIDDLE AGED; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA FOLD; SLIT LAMP; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY; VITRITIS;

EID: 84930936403     PISSN: None     EISSN: 18695760     Source Type: Journal    
DOI: 10.1186/s12348-015-0049-9     Document Type: Article

References (9)

1. London N, Garg S, Moorthy R, Cunningham E (2013) Drug-induced uveitis. J Ophthalmic Inflamm Infect 3:43
2. Menzies AM, Long GV, Murali R (2012) Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 6:391–405
3. Guedj M, Quéant A, Funck-Brentano E, Kramkimel N, Lellouch J, Monnet D, Longvert C, Gantzer A, Brézin A (2014) Uveitis in patients with late-stage cutaneous melanoma treated with Vemurafenib. JAMA Ophthalmol 147 132(12):1421–1425
4. Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK (2014) Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with Vemurafenib. Am J Ophthalmol 150 158(4):831–837
5. Joshi L, Karydis A, Gemenetzi M, Shao EH, Taylor SRJ (2013) Uveitis as a result of MAP kinase pathway inhibition. Case Rep Ophthalmol 4(3):279–282
6. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. NEJM 367:107–114
7. Schoenberger SD, Kim SJ (2013) Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma. Case Reports in Ophthalmological Medicine, vol. 2013, Article ID 673796, 3 pages, 2013
8. McCannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, Wainberg ZA, McCannel CA (2014) Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol 132(8):1005–1009
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245